Marker Therapeutics awarded $2M NIH SBIR grant for MT-601 Phase 1 in CAR-relapsed NHL

Marker Therapeutics, Inc.

Awarded $2 million non-dilutive grant from NIH SBIR to support Phase 1 APOLLO study of MT-601 in NHL patients relapsed after anti-CD19 CAR T therapy.
Grant based on preliminary clinical data (Sept 2023) and non-clinical data (May 2023) showing anti-tumor activity of MT-601.
Company has now received over $19 million in total non-dilutive funding proceeds.
APOLLO study evaluates multiTAA-specific T cell product; initial patients showed objective responses with no CRS or ICANS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.